Azitra to Present at BIO-Europe 2024

AZTR 10.29.2024

SERA-AI Powered Highlights
Drug:ATR-12 ATR-12
Drug:ATR-04 ATR-04
Diseases:Netherton syndrome
Diseases:EGFR inhibitor-induced dermal toxicity
Date of Upcoming Event:2024-11-04
Name of Upcoming Event:BIO-Europe 2024
Full Press ReleaseSEC FilingsOur AZTR Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock
  • 01.14.2025 - Azitra Announces Proposed Public Offering of Common Stock
  • 01.13.2025 - Biotech Showcase 2025

Recent Filings

  • 01.16.2025 - 8-K Current report
  • 01.16.2025 - 424B5 Prospectus [Rule 424(b)(5)]
  • 01.16.2025 - EX-99.1 EX-99.1

BRANFORD, Conn.--(BUSINESS WIRE)--Oct. 29, 2024--Azitra, Inc.(NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the Company will present at BIO-Europe 2024 inStockholm, SwedenonMonday, November 4, 2024at2:30pm CET(8:30am ET).

The corporate update will highlight Azitra’s updates and progress on its pipeline, including ATR-12 in development for Netherton syndrome and ATR-04 in development for epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity.

Details of the presentation are as follows:

BIO-Europe –November 4-6, 2024

Format: Corporate presentation

Date/Time:Monday, November 4, 2024,2:30pm CET(8:30am ET)

Participant:Travis Whitfill, Chief Operating Officer

Location:Room K12, Stockholmsmässan,Stockholm, Sweden

“I am honored to present at BIO-Europe 2024 to give a corporate update,” saidTravis Whitfill, Azitra’s founder and chief operating officer. “We have made extraordinary progress in 2024, including the first patient dosed with ATR-12 in Netherton syndrome and a cleared IND and Fast Track designation from the FDA for ATR-04 for patients suffering from rash due to EGFR inhibitors. I am looking forward to providing further updates and recent developments on our programs.”

To schedule a meeting with the Company’s management at the convention, please submit a meeting request through the BIO One-on-One PartneringTM system or contactstaskey@azitrainc.com.

AboutAzitra, Inc.

Azitra, Inc.is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company's library of strains for drug like molecules. The Company's initial focus is on the development of genetically engineered strains ofStaphylococcus epidermidis, orS. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visithttps://azitrainc.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in our Form 10-Q filed with theSEConAugust 12, 2024.Azitraexplicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241029294091/en/

Norman StaskeyChief Financial Officerstaskey@azitrainc.com

Source:Azitra, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com